Clinical Trial

Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The group used a randomized controlled trial to conduct a post-marketing re-evaluation study of Wangbi granules. The study was conducted to observe the degree of clinical remission in rheumatoid arthritis patients with low disease activity after standard methotrexate and tofacitinib citrate treatment, using a combination of Chinese and Western medicine treatment with Wangbi granules. The study aims to provide evidence-based medical evidence to improve the clinical efficacy of rheumatoid arthritis, enhance the depth of remission, and improve the diagnosis and treatment of rheumatoid arthritis.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-09-14; most recent amendment 2025-01-17.
Status change: Not Yet Recruiting → Recruiting 2025-01-17
Trial Details
NCT Number NCT05540938
Lead Sponsor China-Japan Friendship Hospital
Collaborators: Peking Union Medical College Hospital, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, The 980th Hospital of PLA Joint Logistics Support Force, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Southwest Hospital, China
Conditions Rheumatoid Arthritis
Enrollment 340 participants
Start Date 2023-05-23
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-20